Pertussis

Bacterial Infections of Humans: Epidemiology and Control

Volumn , Issue , 2009, Pages 577-595

  Halperin, Scott A ^a   De Serres, Gaston ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885708164     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-09843-2_27     Document Type: Chapter

References (180)

1. Holmes, W. H., Bacillary and Rickettsial Infections, Macmillan, New York (1940).
2. Lapin, J. H., Whooping Cough, Charles C. Thomas, Springfield, IL (1943).
3. Kloos, W. E., Mohapatra, N., Dobrogosz, W. J., et al., Deoxyribonucleotide sequence relationships among Bordetella species, Int. J. Syst. Bacteriol. 31:173-176 (1981). (Pubitemid 11069659)
4. Parkhill, J., Sebaihia, M., Preston, A., et al., Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica, Nat. Genet. 35:32-40 (2003). (Pubitemid 37048593)
5. Wardlaw, A. C., and Parton, R., The host-parasite relationship in pertussis, in: Pathogenesis and Immunity in Pertussis (A. C. Wardlaw and R. Parton, eds.), pp. 327-352, John Wiley, London (1988).
6. Bordet, J., and Gengou, O., Le microbe de la coqueluche, Ann. Inst. Pasteur 20:731-741 (1906).
7. Pittman, M., The concept of pertussis as a toxin-mediated disease, Pediatr. Infect. Dis. J. 3:467-486 (1984). (Pubitemid 14044510)
8. Dauer, C. C., Reported whooping cough morbidity and mortality in the United States, Public Health Rep. 58:661-676 (1943).
9. Mortimer, E. A., Jr., and Jones, P. K., An evaluation of pertussis vaccine, Rev. Infect. Dis. 1:927-932 (1979).
10. Miller, D. L., Alderslade, R., and Ross, E. M., Whooping cough and whooping cough vaccine: the risks and benefits debate, Epidemiol. Rev. 4:1-24 (1982). (Pubitemid 13249671)
11. Stewart, G. T., Pertussis vaccine: the United Kingdom's experience, in: International Symposium on Pertussis (C. R. Manclark and J. C. Hill, eds.), pp. 262-278, Government Printing Office, Washington, DC (1979).
12. Onorato, I. M., and Wassilak, S. G. F., Laboratory diagnosis of pertussis: the state of the art, Pediatr. Infect. Dis. J. 6:145-151 (1987). (Pubitemid 17116133)
13. Sutter, R. W., and Cochi, S. L., Pertussis hospitalizations and mortality, 1985-1988. Evaluation of the completeness of national reporting, J. Am. Med. Assoc. 267:386-391 (1992).
14. Shaikh, R., Guris, D., Strebel, P. M., and Wharton, M., Underreporting of pertussis deaths in the United States: need for improved surveillance, Pediatrics 101:323-324 (1998).
15. Heininger, U., Stehr, K., Schmidt-Schlapfer, G., et al., Bordetella pertussis infections and sudden unexpected deaths in children, Eur. J. Pediatr. 155:551-533 (1996).
16. Deeks, S., De Serres, G., Boulianne, N., et al., Failure of physicians to consider the diagnosis of pertussis in children, Clin. Infect. Dis. 28: 840-846 (1999). (Pubitemid 29169425)
17. Olson, L. C., Pertussis, Medicine 54:427-469 (1975).
18. Baraff, L. J., Wilkins, J., and Wehrle, P. F., The role of antibiotics, immunizations, and adenoviruses in pertussis, Pediatrics 61:224-230 (1978). (Pubitemid 8291013)
19. Linneman, C. C., Host-parasite interactions in pertussis, in: International Symposium on Pertussis (C. R. Manclark and J. C. Hill, eds.), pp. 3-18, US Government Printing Office, Washington, DC, 1979.
20. Wirsing von König, C. W., Rott, H., Bogaerts, H., and Schmitt, H. J., A serologic study of organism possibly associated with pertussis like coughing, Pediatr. Infect. Dis. J. 17:645-649 (1998). (Pubitemid 28340878)
21. Hallander, H. O., Gnarpe, J., Gnarpe, H., and Olin, P. Bordetella pertussis, Bordetella parapertussis, Mycoplasma pneumoniae and persistant cough in children, Scand. J. Infect. Dis. 31:281-286 (1999). (Pubitemid 29389237)
22. Gay, N. J., and Miller, E., Pertussis transmission in England and Wales, Lancet 355:1553-1554 (2000).
23. Fine, P. E. M., and Clarkson, J. A., Distribution of immunity to pertussis in the population of England and Wales, J. Hyg. 92:21-26 (1984).
24. de Melker, H. E., Versteegh, F. G., Conyn-Van Spaendonck, M. A., et al., Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussi, J. Clin. Microbiol. 38(2):800-806 (2000). (Pubitemid 30082684)
25. Baughman, A. L., Bisgard, K. M., Edwards, K. M., et al., Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States, Clin. Diagn. Lab. Immunol. 11(6):1045-1053 (2004). (Pubitemid 39540842)
26. Mattoo, S., Cherry, J. D., Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella species, Clin. Microbiol. Rev. 18:326-382 (2005). (Pubitemid 40548297)
27. Muller, F. M., Hoppe, J. E., Wirsing von Konig, C. H., Laboratory diagnosis of pertussis: state of the art in 1997, J. Clin. Microbiol. 35:2435-2443 (1997). (Pubitemid 27402638)
28. Hallander, H. O., Reizenstein, E., Renemar, B., et al., Comparison of nasopharyngeal aspirates with swabs for culture of Bordetella pertussis, J. Clin. Microbiol. 31:50-52 (1993). (Pubitemid 23006577)
29. Strebel, P. M., Cochi, S. L., Farizo, K.M., et al., Pertussis inMissouri: evaluation of nasopharyngeal culture, direct fluorescent antibody testing, and clinical case definitions in the diagnosis of pertussis, Clin. Infect. Dis. 16:276-285 (1993). (Pubitemid 23047429)
30. Ewanowich, C. A., Chui, L. W., Paranchych, M. G., et al., Major outbreak of pertussis in northern Alberta, Canada: analysis of discrepant direct fluorescent-antibody and culture results by using polymerase chain reaction methodology, J. Clin. Microbiol. 31: 1715-1725 (1993). (Pubitemid 23182564)
31. He, Q., Mertsola, J., Soini, H., and Vijanen, M. K., Sensitive and specific polymerase chain reaction assays for detection of Bordetella pertussis in nasopharyngeal specimens, J. Pediatr. 124:421-426 (1994). (Pubitemid 24094453)
32. Schlapfer, G., Cherry, J. D., Heininger, V., et al., Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany, Pediatr. Infect. Dis. J. 14:209-214 (1995).
33. Taranger, J., Trollfors, B., Lund, L., et al., Environmental contamination leading to false-positive polymerase chain reaction for pertussis, Pediatr. Infect. Dis. J. 13:936-937 (1994). (Pubitemid 24322798)
34. Schmidt-Schlapfer, G., Liese, J. G., Stojanov, S., et al., Polymerase chain reaction (PCR) compared with conventional identification in culture for detection of Bordetella pertussis in 7153 children, Clin. Microbiol. Infect. 2:462-467 (1997). (Pubitemid 27379985)
35. Halperin, S. A., The control of pertussis-2007 and beyond [Invited Perspective article], N Engl J Med. 356:110-113 (2007).
36. Muyldermans, G, Soetens, O., Antoine, M., et al., External quality assessment for molecular detection of Bordetella pertussis in European laboratories, J. Clin. Microbiol. 43:30-35 (2005). (Pubitemid 40096276)
37. Marchant, C. D., Loughlin, A.M., Lett, S. M., et al., Pertussis inMassachusetts, 1981-1991: incidence, serological diagnosis, and vaccine effectiveness, J. Infect. Dis. 169:1297-1305 (1994).
38. Weiss, A., Hewlett, E. L., Virulence factors of Bordetella pertussis, Annu. Rev. Microbiol. 40:661-686 (1986).
39. Mortimer, E. A., Jr., Pertussis vaccine, in:Vaccines , 2nd ed. (S. A. Plotkin and E. A. Mortimer, Jr., eds.), pp. 91-135, W. B. Saunders, Philadelphia, 1994.
40. Steketee, R. W., Burstyn, D. G., Wassilak, S. G. F., et al., A comparison of laboratory and clinical methods for diagnosing pertussis in an outbreak in a facility for the developmentally disabled, J. Infect. Dis. 157:441-449 (1988). (Pubitemid 18071440)
41. Meade, B. D., Kind, P. D., and Manclark, C. R., Lymphocytosis promoting factor of Bordetella pertussis alters mononuclear phagocyte circulation and response to inflammation, Infect. Immun. 46:733-739 (1984). (Pubitemid 15211076)
42. Spangrude, G. J., Sacchi, F., Hill, H. R., et al., Inhibition of lymphocyte and neutrophil chemotaxis by pertussis toxin. J. Immunol. 135:4135-4143 (1985). (Pubitemid 16250403)
43. Arico, B., and Rappuoli, R., Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes, J. Bacteriol. 169:2847-2853 (1987). (Pubitemid 17104355)
44. Heininger, U., K. Stehr, S. Schmitt-Grohe, C. Lorenz, et al., Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis, Pediatr. Infect. Dis. J. 13:306-309 (1994). (Pubitemid 24113362)
45. Thomas, M. G., Redhead, K., and Lambert, H. P., Human serum antibody responses to Bordetella pertussis infection and pertussis vaccination, J. Infect. Dis. 159:211-218 (1989). (Pubitemid 19049359)
46. Shahin, R. D., Brennan, M. J., Li, Z. M., et al., Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis, J. Exp. Med. 171:63-73 (1990). (Pubitemid 20040599)
47. Emsley, P., McDermott, G., Charles, I. G., et al., Crystallographic characterization of pertactin, a membrane-associated protein from Bordetella pertussis, J. Mol. Biol. 235:772-773 (1996).
48. Cherry, J. D., Bornbein J., Heinninger, U., and Stehr, K., A search for serologic correlates of immunity to Bordetella pertussis cough illnesses, Vaccine 16:1901-1906 (1998). (Pubitemid 28473933)
49. Storsaeter, J., Hallander, H. O., Gustafsson, L., and Olin, P., Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis, Vaccine 15:1907-1916 (1998). (Pubitemid 28473934)
50. Preston, N. W., Effectiveness of pertussis vaccines, Br. Med. J. 2: 11-13 (1965).
51. Centers for Disease Control and Prevention (CDC), Summary of notifiable diseases, United States 2004, Morb. Mortal. Wkly. Rep. 53:1-79 (2006).
52. Centers for Disease Control and Prevention (CDC), Summary of notifiable diseases, United States 2005, Morb. Mortal. Wkly. Rep. 54: 2-92 (2007).
53. Centers for Disease Control and Prevention (CDC), Pertussis-United States, 1997-2000, Morb. Mortal. Wkly. Rep. 51:73-76 (2002).
54. Centers for Disease Control and Prevention (CDC) National, State, and Urban Area Vaccination Coverage Among Children Aged 19-35 Months-United States, 2004 Morb. Mortal. Wkly. Rep. 54:717-721 (2005)
55. Tanaka, M., Vitek, C. R., Pascual, F. B., et al., Trends in pertussis among infants in the United States, 1980-1999, J. Am. Med. Assoc. 290:2968-2975 (2003). (Pubitemid 37505529)
56. Güris, D., Strebel, P. M., Bardenheier, B., et al., Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, Clin. Infect. Dis. 28:1230-1237 (1999). (Pubitemid 29272795)
57. Yih, W. K., Lett, S. M., des Vignes, F. N., et al., The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998, J. Infect. Dis. 182:1409-1416 (2000).
58. Robertson, P.W., Goldberg, H., Jarvie, B. H., et al., Bordetella pertussis infection: a cause of persistent cough in adults, Med. J. Australia 146:522-525 (1987). (Pubitemid 17112924)
59. Mink, C. M., Sirota, N. M., Nugent, S., Outbreak of pertussis in a fully immunized adolescent an adult population, Arch. Pediatr. Adolesc. Med. 148: 153-157 (1994). (Pubitemid 24071384)
60. Schmitt-Grohé, S., Cherry, J. D., Heininger, U., et al., Pertussis in German adults, Clin. Infect. Dis. 21:860-866 (1995).
61. Postels-Multani, S., Schmitt, H. J., Wirsing von König, C. H., et al., Symptoms and complications of pertussis in adults, Infection, 23: 13-16 (1995).
62. Wright, S. W., Edwards, K. M., Decker, M. D., and Zeldin, M. H., Pertussis infection in adults with persistent cough, J. Am. Med. Assoc. 273:1044-1046 (1995).
63. Wirsing von König, C. H., Postels-Multani, S., Bock, H. L., and Schmitt, H. J., Pertussis in adults : frequency of transmission after household exposure, Lancet 346:1326-1329 (1995).
64. Nennig, M. E., Shinefield, H. R., Edwards, K. M., et al., Prevalence and incidence of adult pertussis in an urban population, J. Am. Med. Assoc. 275:1672-1674 (1996). (Pubitemid 26175816)
65. Lieberman, D., Shvartzman, P., Lieberman, D., et al., Etiology of respiratory tract infection in adults in a general practice setting, Eur. J. Clin. Microbiol. Infect. Dis. 17:685-689 (1998). (Pubitemid 29218989)
66. Birkebaek, N. H., Kristiansen, M., Seefeldt, T., et al., Bordetella pertussis and chronic cough in adults, Clin. Infect. Dis. 29:1239-1242 (1999). (Pubitemid 30265645)
67. Mertens, P. L., J. M., Stals, F. S., Schellekens, et al., An epidemic of pertussis among elderly people in a religious institution in The Netherlands, Eur. J. Clin. Microbiol. Infect. Dis. 18:242-247 (1999). (Pubitemid 29527968)
68. Senzilet, L. D., Halperin, S. A., Spika, J. S., et al., Pertussis is a frequent cause of prolonged cough illness in adults and adolescents, Clin. Infect. Dis. 32:1691-1697 (2001). (Pubitemid 32531996)
69. Beynon, K. A., Young, S. A., Laing, R. T., et al., Bordetella pertussis in adult pneumonia patients, Emerg. Infect. Dis. 11:639-641 (2005). (Pubitemid 40462925)
70. Strebel, P., Nordin, J., Edwards, K., et al., Population based incidence of pertussis among adolescents and adults, Minnesota 1995-1996, J. Infect. Dis. 183:1353-1359 (2001). (Pubitemid 32337117)
71. Ward, J. I., Cherry, J. D., Chang, S. J., et al., Immunization of adolescents and adults with an acellular pertussis vaccine: results of a national randomized protective efficacy trial, N. Engl. J. Med. 353:1555-1563 (2005). (Pubitemid 41434634)
72. Nardone, A., Pebody, R. G., Maple, P. A., et al., Sero-epidemiology of Bordetella pertussis in England and Wales, Vaccine 12:22:1314-1319 (2004). (Pubitemid 38296676)
73. Pebody, R. G., Gay, N. J., Giammanco, A., et al., The seroepidemiology of Bordetella pertussis infection in Western Europe, Epidemiol. Infect. 133:159-171 (2005). (Pubitemid 40276986)
74. Vitek, C. R., Pascual, F. B., Baughman, A. L., and Murphy, T. V., Increase in deaths from pertussis among young infants in the United States in the 1900s, Ped. Infect. Dis. 22:628-634 (2003). (Pubitemid 36900210)
75. Srivasta, P., Unpublished data from the Centers for Disease Control and Prevention, personal communication (2007).
76. Bassili, W. R., and Stewart, G. T., Epidemiological evaluation of immunization and other factors in the control of whooping cough, Lancet 1:471-474 (1976).
77. Ehrengut, W., Whooping cough vaccination: comment on report from the Joint Committee on Vaccination and Immunisation, Lancet 1:370-371 (1978). (Pubitemid 8273455)
78. Gordon, J. E., and Hood, R. I., Whooping cough and its epidemiological anomalies, Am. J. Med. Sci. 222:333-361 (1951).
79. Stewart, G. T.,Whooping cough and pertussis vaccine : a comparison of risks and benefits in Britain during the period 1968-1983, Dev. Biol. Stand. 61:395-405 (1984).
80. Miller, E., Vurdien , J. E., White, J. M., The epidemiology of pertussis in England and Wales, Commun. Dis. Rep. 2:R152-154 (1992).
81. World Health Organization. Statistics on pertussis. http://www.who.int/ immunizationmonitoring/diseases/pertussis/en/index.html accessed October 17 (2005).
82. Mikelova, L. K., Halperin, S. A., Scheifele, D., et al., Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada, J. Pediatr. 143:576-581(2003). (Pubitemid 37452782)
83. Sako, W., Studies on pertussis immunization, J. Pediatr. 30:29-40 (1947).
84. Gustafsson, L., Hallander, H. O., Olin, P., et al., A controlled trial of a two-component acellular, a five-component acellular, and a wholecell pertussis vaccine, N. Engl. J. Med. 334:349-355 (1996). (Pubitemid 26049587)
85. Greco, D., Salmaso, S., Mastrantonio, P., et al., A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N. Engl. J. Med. 334:341-348 (1996). (Pubitemid 26053148)
86. Clark, A. C., Bradford, W. L., and Berry, G. P., An epidemiological study of an outbreak of pertussis in a public school, Am. J. Public Health 36:1156-1162 (1946).
87. Centers for Disease Control and Prevention (CDC), Pertussis outbreak among adults at an oil refinery-Illinois, August-October 2002, Morb. Mortal. Wkly. Rep. 52:1-4 (2003).
88. Centers for Disease Control and Prevention (CDC), Schoolassociated pertussis outbreak-Yavapai County, Arizona, September 2002-February 2003, Morb. Mortal. Wkly. Rep. 53:216-219 (2004).
89. Wheeler, J. G., Tran, T. C., North, P., et al., Barriers to public health management of a pertussis outbreak in Arkansas, Arch. Pediatr. Adolesc. Med. Feb 158(2):146-152 (2004). (Pubitemid 38173968)
90. Christie, C. D. C., Marx, M. L., Marchant, C. D., and Reising, S. F., The 1993 epidemic of pertussis in Cincinnati. Resurgence of disease in a highly immunized population of children, N. Engl. J. Med. 331:16-21 (1994).
91. Centers for Disease Control and Prevention, Resurgence of pertussis-United States, 1993, Morb. Mortal. Wkly. Rep. 42:952-953, 959-960 (1993).
92. Centers for Disease Control and Prevention, Pertussis outbreaks-Massachusetts and Maryland, 1992, Morb. Mortal. Wkly. Rep. 42:197-200 (1993).
93. Centers for Disease Control and Prevention (CDC), Pertussis outbreak-Vermont 1996, Morb. Mortal. Wkly. Rep. 46:822-826 (1997).
94. Skowronski, D. M., De Serres, G., MacDonald, et al., The changing age and seasonal profile of pertussis in Canada, J. Infect. Dis. 185(10):1448-1453 (2002). (Pubitemid 34507967)
95. Ntezayabo, B., De Serres, G., Duval, B., Pertussis resurgence in Canada largely caused by a cohort effect, Pediatr. Infect. Dis. J. 22:22-27 (2003). (Pubitemid 36091773)
96. Farizo, K. M., Cochi, S. L., Zell, E. R., et al., Epidemiological features of pertussis in the United States, 1980-1989, Clin. Infect. Dis. 14:708-719 (1992).
97. Kendrick P, Elderling G., Significance of bacteriological methods in the diagnosis and control of whooping cough. Am. J. Public Health 25:147-155 (1935)
98. Kendrick P, Eldering G. A study in active immunization against pertussis, Am. J. Hyg. B., 29:133-159 (1939).
99. Huovila, R., The effect of early erythromycin treatment on the infectiousness of whooping cough patients, Acta Paediatr. Scand. Suppl. 298:10-12 (1982). (Pubitemid 13186814)
100. Kwantes, W., Joynson, D. H. M., and Williams, W. O., Bordetella pertussis isolation in general practice: 1997-79 whooping cough epidemic in West Glamoran, J. Hyg. Camb. 90:149-158 (1983). (Pubitemid 13086173)
101. Preziosi, M. P., and Halloran, M. E., Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness, Vaccine 21:1853-1861 (2003). (Pubitemid 36428775)
102. He, Q., Arvilommi, H., Viljanen, M. K., and Mertsola, J., Outcome of Bordetella infections in vaccinated children: effects of bacterial number in the nasopharynx and patient age, Clin. Diagnost. Lab. Immunol. 6:534-536 (1999). (Pubitemid 29330737)
103. Expanded Programme on Immunization, EPI for the 1990s, World Health Organization, Geneva (1992).
104. Fine, P. E. M., and Clarkson, J. A., Seasonal influences on pertussis, Int. J. Epidemiol. 15:237-247 (1986). (Pubitemid 16001825)
105. Clegg, E. J., Infectious disease mortality in two Outer Hebridean islands: 1. measles, pertussis and influenza, Ann. Hum. Biol. 30:455-471 (2003). (Pubitemid 36872486)
106. Bradford, W. L., Use of convalescent blood in whooping cough, Am. J. Dis. Child. 50:918-928 (1935).
107. Kendrick, P. L., Secondary attack rates from pertussis in vaccinated and unvaccinated children, Am. J. Hyg. 32:89-91 (1940).
108. Church, M. A., Evidence of whooping-cough-vaccine efficacy from the 1978 whooping-cough epidemic in Hertfordshire, Lancet 2:188-190 (1979).
109. Noble, G. R., Bernier, R. H., Esber, E. C., et al., Acellular and wholecell pertussis vaccines in Japan: report of a visit by US scientists, J. Am. Med. Assoc. 257:1351-1356 (1987). (Pubitemid 17024854)
110. Wortis, N., Strebel, P. M.,Wharton, M., et al., Pertussis deaths: report of 23 cases in the United States, 1992 and 1993, Pediatrics 97:607-612 (1996). (Pubitemid 26138087)
111. Halperin, S. A., Wang, E. E. L., Law, B., et al., Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program-Active (IMPACT), Clin. Infect. Dis. 28:1238-1243 (1999). (Pubitemid 29272796)
112. De Serres, G., Shadmani, R., Duval, B., et al., Morbidity of pertussis in adolescents and adults, J. Infect Dis. 182:174-179 (2000). (Pubitemid 30497802)
113. Rosenfeld, G. B., and Bradley, C., Childhood behavior sequelae of asphyxia in infancy with special reference to pertussis and asphyxia neonatorum, Pediatrics 2:74-83 (1948).
114. Byers, R. K., and Rizzo, N. D., A follow-up study of pertussis in infancy, N. Engl. J. Med. 242:887-891 (1950).
115. Litvak, A. M., Gibel, H., Rosenthal, S. E., and Rosenblatt, P., Cerebral complications in pertussis, J. Pediatr. 32:357-379 (1948).
116. Miller, D., Wadsworth, J., Diamond, J., and Ross, E., Pertussis vaccine and whooping cough as risk factors for acute neurological illness and death in young children, Dev. Biol. Stand. 61:385-394 (1985).
117. Nelson, J. D., The changing epidemiology of pertussis in young infants. The role of adults as reservoirs of infection, Am. J. Dis. Child. 132:371-373 (1978). (Pubitemid 9129606)
118. Trollfors, B., and Rabo, E., Whooping cough in adults, Br. Med. J. 283:696-697 (1981). (Pubitemid 11051404)
119. Mortimer, E. A., Jr., Perspectives. Pertussis and its prevention: a family affair, J. Infect. Dis. 161:473-479 (1990). (Pubitemid 20107948)
120. Long, S. S., Welkon, C., and Clark, J. L., Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology, J. Infect. Dis. 161:480-486 (1990). (Pubitemid 20107949)
121. Mink, C. A. M., Cherry, J. D., Christenson, P., et al., A search for Bordetella pertussis infection in university students, Clin. Infect. Dis. 14:464-471 (1992).
122. Aoyama, T., Takeuchi, Y., Goto, A., et al., Pertussis in adults, Am. J. Dis. Child. 146:163-166 (1992).
123. Cromer, B. A., Goydos, J., Hackell, J., et al., Unrecognized pertussis infection in adolescents, Am. J. Dis. Child. 147:575-577 (1993). (Pubitemid 23137618)
124. Halperin, S. A., and Marrie, T. J., Pertussis encephalopathy in an adult: case report and review, Rev. Inf. Dis. 13:1043-1047 (1991).
125. Skowronski, D. M., Buxton, J. A., Hestrin, M., et al., Carotid artery dissection as a possible severe complication of pertussis in an adult: clinical case report and review, Clin. Infect. Dis. 36:e1-e4 (2003). Available from: URL: http://www.journals.uchicago.edu/CID/journal/issues/v36n1/020600/020600.hmtl.
126. Olin, P., Rasmussen, F., Gustafsson, L., et al., Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines, Lancet 350: 1569-1577 (1997). (Pubitemid 28036599)
127. Knowles, K., Lorange, M., Matthews, R. C., and Preston, N. W., Characterization of outbreak and vaccine strains of Bordetella pertussis-Quebec, Can. Comm. Dis. Rep. 91-21:182-187 (1993).
128. Winsnes, R., Serological responses to pertussis, in: Pathogenesis and Immunity in Pertussis (A. C. Wardlaw and R. Parton, eds.), pp. 283-307, John Wiley, New York (1988).
129. Mills, K H. G., Barnard, A. L., Watkins, J., and Redhead, K., Cell mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model, Infect. Immun. 61:399 (1993).
130. Redhead, K., Barnard, A., Watkins, J., and Miles, K. H. G., Effective immunization against Bordetella pertussis is dependent on induction of cell-mediated immunity, Infect. Immun. 61:3190 (1993).
131. Mills, K. H. G., and Redhead, K., Cellular immunity in pertussis, J. Med. Microbiol. 39:163-164 (1993). (Pubitemid 23279690)
132. Butler, N. R., Haslum,M., Golding, J., and Stewart-Brown, S., Recent findings from the 1970 child health and education study: preliminary communication, J. Roy. Soc. Med. 75:781-784 (1982). (Pubitemid 13201074)
133. Britten, N., and Wadsworth, J., Long-term respiratory sequelae of whooping cough in a nationally representative sample, Br. Med. J. 292:441-444 (1986). (Pubitemid 16139288)
134. Johnston, I. D. A., Bland, J. M., and Ingram, D., Effect of whooping cough in infancy on subsequent lung function and bronchial reactivity, Am. Rev. Respir. Dis. 134:270-275 (1986). (Pubitemid 16046908)
135. Granstrom, G., and Granstrom, M., Effect of erythromycin treatment on antibody responses in pertussis, J. Infect. Dis. 26:453-457 (1994). (Pubitemid 24245134)
136. World Health Organization. 1991. WHO meeting on case definition of pertussis: Geneva, 10-11 January 1991. Issue no. MIN/EP1/PERT/91.1. WHO Geneva, Switzerland.
137. Centers for Disease Control and Prevention (CDC), Guidelines for the Control of Pertussis Outbreaks, Centers for Disease Control and Prevention, Atlanta, GA, 2000 (amendments made in 2005 and 2006), www.cdc.gov/nip/ publications/pertussis/guide.htm.
138. Halperin, S. A, Bortolussi, R., Langley, J., et al., Seven days of erythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis infections, Pediatrics 100:65-71 (1997). (Pubitemid 27291009)
139. Langley, J. M., Halperin, S. A., Boucher, F. D., and Smith, B., Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC), Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis, Pediatrics 114:e96-101 (2004). Available from: URL: http://www.pediatrics.org/cgi/content/full/114/1/e96.
140. Halperin, S. A., Bortolussi, R., Langley, J. M., et al., randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive Bordetella pertussis infection, Pediatrics 104(4):e42. (1999). Available from: URL: http://www.pediatrics.org/ cgi/content/full/104/4/e42.
141. Lebel, M. H., and Mehra, S., Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial, Pediatr. Infect. Dis. J. 20:1149-1154 (2001). (Pubitemid 34016428)
142. Dodhia, H., Miller, E. Review of the evidence for the use of erythromycin in the management of persons exposed to pertussis. Epidemiol Infect 120:143-149 (1998). (Pubitemid 28192626)
143. Steketee, R. W., Wassilak, S. Adkins, W. N., et al., Evidence for high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled, J. Infect. Dis. 157:434-440 (1988). (Pubitemid 18071439)
144. Sprauer, M. A., Cochi, S. L., Zell, E. R. et al., Prevention of secondary transmission of pertussis in households with early use of erythromycin. Am. J. Dis. Child. 146:177-181 (1992).
145. De Serres, G., Boulianne, N., Duval, B. Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr. Infect. Dis. J. 14:969-75 (1995).
146. Morris, D., and McDonald, J. C., Failure of hyperimmune gamma globulin to prevent whooping cough, Arch. Dis. Child. 32:236-239 (1957).
147. Granstrom, M., Olinder-Nielsen, A. M., Holmblad, P., et al., Specific immunoglobulin for treatment of whooping cough, Lancet 338:1230-1233 (1992).
148. Ichimaru, T., Ohara, Y., Hojo, M., et al., Case report. Treatment of severe pertussis by administration of specific gamma globulin with high titer anti-toxin antibody, Acta Paediatr. 82:1076-1078 (1993). (Pubitemid 24051404)
149. Bruss J., Malley R., Halperin, S., et al., Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin, Pediatr. Infect. Dis. J. 18:505-511 (1999). (Pubitemid 29277613)
150. Halperin, S. A., Vaudry,W., Boucher, F. C., et al., Is pertussis immune globulin efficacious for the treatment of hospitalized infants with pertussis? No answer yet, Pediatr. Infect. Dis. J. 26:79-81 (2007). (Pubitemid 46045758)
151. Onorato, I.M.,Wassilak, S. G., andMeade, B., Efficacy of whole cell pertussis vaccine in preschool children in the United States, J. Am. Med. Assoc. 267:2745-2749 (1992).
152. Cherry, J. D., The epidemiology of pertussis and pertussis vaccine in the United Kingdom and the United States: a comparative study, Current Problems in Pediatrics 14:1-78 (1984).
153. Hirtz, D. G., Nelson, K. B., and Ellenberg, J. H., Seizures following childhood immunizations, J. Pediatr. 102:14-18 (1983). (Pubitemid 13167840)
154. Cody, C. L., Baraff, L. J., Cherry, J. D., et al., Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children, Pediatrics 68:650-660 (1981). (Pubitemid 11029708)
155. Department of Health and Social Security, Committee on Safety of Medicines and Joint Committee on Vaccination and Immunization, Whooping Cough, Her Majesty's Stationery Office, London (1981).
156. Miller, D., Madge, N., Diamond, J., et al., Pertussis immunization and serious acute neurological illness in children, Br. Med. J. 307:1171-1176 (1993). (Pubitemid 23319334)
157. Howson, C. P., and Fineberg, H. V., Adverse events following pertussis and rubella vaccines: summary of a report of the Institute of Medicine, J. Am. Med. Assoc., 267:392-396 (1992).
158. Halsey, N. A., Chesney, P. J., Gerber, M. A., et al., The relationship between pertussis vaccine and central nervous system sequelae: continuing assessment. Committee on Infectious Diseases, American Academy of Pediatrics, Pediatrics 97:279-281 (1996). (Pubitemid 26049668)
159. Kanai, K., Japan's experience in pertussis epidemiology and vaccination in the past thirty years, Jpn. J. Sci. Biol. 33:107-143 (1980). (Pubitemid 10030863)
160. Romanus, V., Jonsell, R., and Bergquist, S. E., Pertussis in Sweden after the cessation of general immunization in 1979, Pediatr. Infect. Dis. J. 6:364-371 (1987). (Pubitemid 17070042)
161. Edwards, K. M., Meade, B. D., Decker, M. D., et al., Comparison of 13 acellular pertussis vaccines: overview and serologic response, Pediatrics 96(Suppl.):548-557 (1995).
162. Decker, M. D., Edwards, K. M., Steinhoff, M. C., et al., Comparison of thirteen acellular pertussis vaccines: adverse reactions, Pediatrics 96(Suppl.):557-566 (1995).
163. Cherry, J. D., Comparative efficacy of acellular pertussis vaccines: a analysis of recent trials, Pediatr. Infect. Dis. J. 16:S90-96 (1997). (Pubitemid 27175031)
164. Trollfors, B., Taranger, J., Lagergard, T., et al., A placebo-controlled trial of a pertussis-toxoid vaccine, N. Engl. J. Med. 333:1045-1050 (1995).
165. Simondon, F., Preziosi, M. P., Yam, A., et al., A randomized doubleblind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal,Vaccine 15:1606-1612 (1997). (Pubitemid 27445741)
166. Liese, J. G., Meschievitz, C. K., Harzer, E., et al., Efficacy of a twocomponent acellular pertussis vaccine in infants, Pediatr. Infect. Dis. J. 16:1038-1044 (1997). (Pubitemid 27494960)
167. Stehr, K., Cherry, J. D., Heininger, U., et al., Comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine, Pediatrics 101:1-11 (1998). (Pubitemid 28030315)
168. Salmaso, S., Mastrantonio, P., Tozzi, A. E., et al., Stage III Working Group. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience, Pediatrics 108:e81 (2001).
169. Le Saux, N., Barrowman, N. J., Moore, D. L., et al., Decrease in hospital admissions for febrile seizures and reports of hypotonichyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT. Pediatrics 112:e348-353 (2003). Available from: URL: http://www.pediatrics.org/cgi/content/full/112/5/ e348.
170. Moore, D. L., Le Saux, N., Scheifele, D., et al., Lack of evidence of encephalopathy related to pertussis vaccine: active surveillance by IMPACT, Canada, 1993-2002, Pediatr. Infect. Dis. J. 23:568-571 (2004). (Pubitemid 38802306)
171. Halperin, S. A., Scheifele, D., Barreto, L., et al., Comparison of a fifth dose of a five-component acellular or a whole-cell pertussis vaccine in children four to six years of age, Pediatr. Inf. Dis. J. 18:772-779 (1999). (Pubitemid 29428531)
172. Scheifele, D. W., Halperin, S. A., and Ferguson, A. C., Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens, Vaccine 19:4720-4726 (2001). (Pubitemid 32800756)
173. Halperin, S. A., Scheifele, D., Mills, E., et al., Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine, Vaccine 21:2298-2306 (2003). (Pubitemid 36561321)
174. Skowronski, D. M., Remple, V. P., Macnabb, J., et al., Injectionsite reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact, Pediatrics 112:e453-e459 (2003) Available from: URL: http://www.pediatrics.org/cgi/content/full/112/6/e453.
175. National Advisory Committee on Immunization (NACI), Prevention of pertussis in adolescents and adults, Can. Commun. Dis. Rep. 29(ACS 5,6):1-9 (2003).
176. Centers for Disease Control and Prevention, Preventing tetanus, diphtheria, and pertussis among adolescents: Use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm. Rep. 55(RR-3):1-44 (2006).
177. Centers for Disease Control and Prevention, Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for Use of Tdap Among Health-Care Personnel, MMWR Recomm. Rep. 55(RR-17):1-37 (2006).
178. Institute of Medicine. (Howson, C. P., Howe, C. J., and Fineberg, H. V., editors). Adverse Effects of Pertussis and Rubella Vaccine, National Academy Press, Washington, DC. (1991).
179. Mortimer, E. A., Jr., Pertussis vaccine, in:Vaccines , 2nd ed. (S. A. Plotkin and E. A. Mortimer, editors) pp. 91-135, W. B. Saunders, Philadelphia (1994).
180. Wardlaw, A. C., and Parton, R., editors. Pathogenesis and Immunity in Pertussis, John Wiley, London (1988).